By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Shionogi & Co., Ltd. 

1-8, Doshomachi 3-Chome
Chuo-ku
Osaka     541-0045  Japan
Phone: 81-0-6-6202-2161 Fax: 81-0-6-6229-9596


SEARCH JOBS



Segment
Research





Company News
Shionogi Release: Cefiderocol, A Novel Investigational Siderophore Cephalosporin, Demonstrated Potent Activity Against Multi-Drug Resistant Gram-Negative Pathogens 10/26/2016 7:51:31 AM
Shionogi Release: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation 9/7/2016 3:09:38 PM
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi 6/13/2016 9:53:07 AM
Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation 6/6/2016 10:10:27 AM
Shionogi Release: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 5/24/2016 8:55:16 AM
Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation 3/30/2016 6:16:06 AM
Shire (SHPG) Partner, Shionogi, Submits New Drug Application In Japan For ADHD Treatment For Children 2/11/2016 6:37:10 AM
Response Biomedical (RBM.V) Announces Strategic Alliances In Japan With Alere (ALR) And Long Time Partner Shionogi 12/9/2015 7:45:45 AM
Egalet Cuts Off Drug Partnership with Shionogi 12/4/2015 6:13:55 AM
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3/30/2015 6:05:06 AM
1234567
//-->